Takeda stakes more than $11B on cancer drugs from China

The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be “transformative” for its oncology portfolio.

Metsera strengthens case for Pfizer buyout with latest study data

Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial

December 18, 2025

Shettima charges NDPHC to align with Nigeria’s energy development goals – EnviroNews

December 18, 2025

Source link

Takeda stakes more than $11B on cancer drugs from China

Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial

Shettima charges NDPHC to align with Nigeria’s energy development goals – EnviroNews

AI heavyweights call for end to ‘superintelligence’ research

No, ICE (Probably) Didn’t Buy Guided Missile Warheads

No, ICE (Probably) Didn’t Buy Guided Missile Warheads

Leave a Reply Cancel reply

RECOMMENDED NEWS

Cityscape Bahrain 2025 set to ignite Bahrain’s real estate scene with its largest edition yet

Top 10 Nigerian states with the lowest unemployment rate

Audi’s Rebrand in China Points to Bigger Changes in the Auto Industry

ACA co-sponsors the AVCA Conference 2023 – Investment Management in Africa

POPULAR NEWS

Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

The world’s top 10 most valuable car brands in 2025

Top 10 African countries with the highest GDP per capita in 2025

Global ranking of Top 5 smartphone brands in Q3, 2024

When Will SHIB Reach $1? Here’s What ChatGPT Says

Takeda stakes more than $11B on cancer drugs from China

Related posts

AI heavyweights call for end to ‘superintelligence’ research

No, ICE (Probably) Didn’t Buy Guided Missile Warheads

Leave a Reply Cancel reply

RECOMMENDED NEWS

POPULAR NEWS